Trials / Completed
CompletedNCT03137407
Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Revance Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Botulinum Toxins, Type A | Intramuscular injection |
| BIOLOGICAL | Placebo | Intramuscular injection |
Timeline
- Start date
- 2017-06-12
- Primary completion
- 2018-02-20
- Completion
- 2018-02-20
- First posted
- 2017-05-02
- Last updated
- 2023-09-18
- Results posted
- 2023-08-28
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03137407. Inclusion in this directory is not an endorsement.